MGNXMacroGenics, Inc.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pip…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year? Here is how MacroGenics (MGNX) and CareDx (CDNA) have performed compared to their sector so far this year. | ||
 Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst? On August 11, Gilead Sciences, Inc. (NASDAQ:GILD) exercised its option to exclusively license a preclinical bispecific program targeting solid tumors using MacroGenics, Inc. (NASDAQ:MGNX)’s proprietary TRIDENT platform. The decision triggered a $10 million milestone payment to MacroGenics, injecting momentum into the companies’ 2022 collaboration. That broader agreement spans three programs, including clinical-stage CD123 x CD3 […] | IInsider Monkey | |
 MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates MacroGenics (MGNX) delivered earnings and revenue surprises of +32.50% and -25.45%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Sanara MedTech Inc. (SMTI) Tops Q2 Earnings Estimates Sanara MedTech (SMTI) delivered earnings and revenue surprises of +150.00% and -4.30%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Beats Revenue Estimates Maravai LifeSciences (MRVI) delivered earnings and revenue surprises of +60.00% and +4.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
IInsider Monkey | ||
EExec Edge | ||
EExec Edge | ||